Result of AGM

Renalytix PLC
15 December 2023
 

Renalytix plc

("Renalytix" or the "Company") 

 

Result of AGM

 

LONDON and SALT LAKE, 15 December 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The results of the AGM are detailed below:


 For

 % voted in favour

 

 Against

 % voted against

 Withheld

Ordinary resolutions

 






1 Accept Financial Statements and Statutory Reports

      40,118,702

99.94%


24,743

0.06%

                   67,418

2 Approve Remuneration Report

      39,959,034

99.44%


226,856

0.56%

                   24,973

3 Re-elect Cathy Coste

      39,058,428

97.29%


1,086,363

2.71%

                   66,072

4 Withdrawn

      -

-


-

-

                   -

5 Reappoint EY

      39,266,710

97.73%


910,387

2.27%

                   33,766

6 Reappoint PKF Littlejohn LLP as Auditors

      40,142,582

99.91%


37,614

0.09%

                   30,667

7 Authorise Board to Fix Remuneration of Auditors

      40,105,519

99.81%


77,729

0.19%

                   27,615

8 Authorise Issue of Equity

      38,484,392

95.78%


1,697,234

4.22%

                   29,237








Special resolutions

 






9 Authorise Issue of Equity without Pre-emptive Rights

      38,467,804

95.74%


1,710,946

4.26%

                   32,113

10 Authorise Market Purchase of Ordinary Shares

39,597,340

99.87%


51,284

0.13%

                 562,239

11 Adoption of new articles

40,059,859

99.74%


104,681

0.26%

                   46,323

 

 

For further information, please contact: 

 

Renalytix plc  

www.renalytix.com

James McCullough, CEO  

Via Walbrook PR



Stifel (Nominated Adviser, Joint Broker) 

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea




Investec Bank plc (Joint Broker) 

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra




Walbrook PR Limited 

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings / Charlotte Edgar

Mob: 07980 541 893 / 07407 804 654 / 07884 664 686  

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings